Nuvectis Pharma, Inc. - Common Stock — 분기별 재무제표 (NASDAQ:NVCT) | MetaTrader

전체 차트 열기 Full chart

뉴스

Wall Street Analysts Think Nuvectis Pharma (NVCT) Could Surge 57%: Read This Before Placing a Bet

Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade

Nuvectis initiates phase 1b trial combining NXP900 with osimertinib

누벡티스 파마, H.C. 웨인라이트 ’매수’ 등급 재확인

Nuvectis Pharma stock rating reiterated at Buy by H.C. Wainwright

카플란, Nuvectis Pharma(NVCT) 주식 64,240달러 상당 매수

Nuvectis Pharma 회장, 28,600달러 상당의 주식 매입

Nuvectis Pharma 이사, NVCT 주식 7.5만 달러 매수

H.C. Wainwright, Nuvectis Pharma에 ’매수’ 등급 재확인, 목표가 $10

H.C. Wainwright reiterates Buy rating on Nuvectis Pharma stock at $10 target

Nuvectis Pharma adds former Intra-Cellular exec to board of directors

Nuvectis initiates phase 1b program for cancer drug NXP900